Sign inJoin Free
DashboardSign out
Free Lesson Preview
Module 1: Lesson 1
Diversity, Inclusion, and Vulnerable Populations
Apply ICH E6(R3) Principle 1.4 to design enrollment strategies that ensure diverse participation while implementing appropriate safeguards for vulnerable populations.
Who participates determines who benefits
Every clinical trial generates knowledge. But that knowledge is not universal. The data tell us how a treatment works in the people who were studied, and we can only extrapolate so far to populations who were not represented in the research.
This is not an abstract statistical concern. It is a matter of justice and scientific integrity with real consequences for patients. A blood pressure medication tested predominantly in middle-aged white men may behave differently in elderly black women. A cancer therapy evaluated in patients with excellent kidney function may require dose adjustments for the many real-world patients with renal impairment. When trial populations do not reflect the people who will ultimately use a treatment, we generate evidence that serves some patients well and others poorly.
For decades, clinical trials systematically under-enrolled women, elderly patients, racial and ethnic minorities, and people with comorbidities. The consequences became apparent when approved treatments reached diverse patient populations and performed differently than expected, sometimes less effectively, sometimes with unexpected toxicities. The research enterprise was generating answers, but not answers that applied equally to everyone.
ICH E6(R3) addresses this directly through Sub-principle 1.4, a new requirement that participant selection should reflect the intended treatment population. This lesson examines what that principle requires and how it must be balanced with the special protections owed to vulnerable populations.
What you will learn
By the end of this lesson, you will be able to:
Good Clinical Practice (GCP)
Full course · ICH E6(R3) Principles